View of Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Return to Article Details Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study Download Download PDF